However, no previous studies have focused explicitly on the relationship between plasmatic levels of HSP90α at diagnosis and the prognosis of advanced lung cancer patients treated with PD1/PD-L1 inhibitors plus chemotherapy. The gene discussed is PDCD1; the disease is lung carcinoma.